Ipsen will pay $450 million upfront to buy Kartos Therapeutics and its MDM2 protein-targeting drug c...
Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
Ipsen will pay $450 million upfront to buy Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016.
Author: Endpoints News
Read Original Article